Targeting class Ia PI3K isoforms selectively impairs cell growth, survival, and migration in glioblastoma

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Höland, Katrin ^a   Boller, Danielle ^b   Hagel, Christian ^c   Dolski, Silvia ^d   Treszl, András ^c   Pardo, Olivier E ^e   Ćwiek, Paulina ^a   Salm, Fabiana ^a   Leni, Zaira ^a   Shepherd, Peter R ^f   Styp Rekowska, Beata ^g   Djonov, Valentin ^g   Von Bueren, André O ^h   Frei, Karl ^d   Arcaro, Alexandre ^a,b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY OF AUCKLAND   (New Zealand)

^g UNIVERSITY OF BERN   (Switzerland)

^h UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ISOENZYME; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PHOSPHOINOSITIDE 3 KINASE P110ALPHA; PHOSPHOINOSITIDE 3 KINASE P110BETA; PHOSPHOINOSITIDE 3 KINASE P110DELTA; PROTEIN KINASE B; S6 KINASE; UNCLASSIFIED DRUG; 3-(4-MORPHOLINOTHIENO(3,2-D)PYRIMIDYL-2-YL)PHENOL; AKT1 PROTEIN, HUMAN; HYDRAZONE DERIVATIVE; MORPHOLINE DERIVATIVE; PIK 75; PROTEIN KINASE INHIBITOR; SULFONAMIDE; THIOPHENE DERIVATIVE; TUMOR PROTEIN;

ANCHORAGE INDEPENDENT GROWTH; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ANALYSIS; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; INTRACELLULAR SIGNALING; MAJOR CLINICAL STUDY; MALE; MIGRATION INHIBITION; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; SURVIVAL PREDICTION; SURVIVAL TIME; TUMOR REGRESSION; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN TUMOR; CELL ADHESION; CELL DIVISION; CELL MOTION; CHICK EMBRYO; DRUG EFFECTS; DRUG SCREENING; ENZYME INDUCTION; ENZYME SPECIFICITY; ENZYMOLOGY; PATHOLOGY; PHYSIOLOGY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BRAIN NEOPLASMS; CELL ADHESION; CELL DIVISION; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; CHICK EMBRYO; CLASS IA PHOSPHATIDYLINOSITOL 3-KINASE; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INDUCTION; GLIOBLASTOMA; HUMANS; HYDRAZONES; MORPHOLINES; NEOPLASM PROTEINS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SUBSTRATE SPECIFICITY; SULFONAMIDES; THIOPHENES; TUMOR CELLS, CULTURED;

EID: 84899506504     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0094132     Document Type: Article

References (59)

1. Central Brain Tumor Registry of the United States CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004-22007.
2. Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359: 492-507.
3. DeAngelis LM (2001) Brain tumors. N Engl J Med 344: 114-123.
4. Lee JC, Vivanco I, Beroukhim R, Huang JH, Feng WL, et al. (2006) Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med 3: e485.
5. Halatsch ME, Schmidt U, Behnke-Mursch J, Unterberg A, Wirtz CR (2006) Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. Cancer Treat Rev 32: 74-89. (Pubitemid 43362229)
6. Choe G, Horvath S, Cloughesy TF, Crosby K, Seligson D, et al. (2003) Analysis of the phosphatidylinositol 39-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 63: 2742-2746. (Pubitemid 36667143)
7. Chakravarti A, Zhai G, Suzuki Y, Sarkesh S, Black PM, et al. (2004) The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol 22: 1926-1933. (Pubitemid 41095185)
8. Bowers DC, Fan S, Walter KA, Abounader R, Williams JA, et al. (2000) Scatter factor/hepatocyte growth factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-kinase- and AKT-dependent pathways. Cancer Res 60: 4277-4283. (Pubitemid 30636617)
9. Chakravarti A, Loeffler JS, Dyson NJ (2002) Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 62: 200-207. (Pubitemid 34074005)
10. Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, et al. (2001) Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 17: 615-675. (Pubitemid 33096187)
11. Höland K, Salm F, Arcaro A (2011) The Phosphoinositide 3-Kinase Signaling Pathway as a Therapeutic Target in Grade IV Brain Tumors. Curr Cancer Drug Targets 11: 894-918.
12. The Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.
13. Knobbe CB, Reifenberger G (2003) Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3 9-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas. Brain Pathol 13: 507-518. (Pubitemid 37420695)
14. Broderick DK, Di C, Parrett TJ, Samuels YR, Cummins JM, et al. (2004) Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res 64: 5048-5050. (Pubitemid 39006515)
15. Hartmann C, Bartels G, Gehlhaar C, Holtkamp N, von Deimling A (2005) PIK3CA mutations in glioblastoma multiforme. Acta Neuropathol 109: 639-642. (Pubitemid 40974153)
16. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, et al. (1998) Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95: 29-39. (Pubitemid 28458022)
17. Maehama T, Dixon JE (1998) The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273: 13375-13378. (Pubitemid 28268370)
18. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, et al. (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554. (Pubitemid 38541907)
19. Knobbe CB, Trampe-Kieslich A, Reifenberger G (2005) Genetic alteration and expression of the phosphoinositol-3-kinase/Akt pathway genes PIK3CA and PIKE in human glioblastomas. Neuropathol Appl Neurobiol 31: 486-490. (Pubitemid 41337782)
20. Mueller W, Mizoguchi M, Silen E, D'Amore K, Nutt CL, et al. (2005) Mutations of the PIK3CA gene are rare in human glioblastoma. Acta Neuropathol 109: 654-655. (Pubitemid 40974155)
21. Gallia GL, Rand V, Siu IM, Eberhart CG, James CD, et al. (2006) PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. Mol Cancer Res 4: 709-714. (Pubitemid 44683311)
22. Mizoguchi M, Nutt CL, Mohapatra G, Louis DN (2004) Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas. Brain Pathol 14: 372-377. (Pubitemid 39524966)
23. Hui AB, Lo KW, Yin XL, Poon WS, Ng HK (2001) Detection of multiple gene amplifications in glioblastoma multiforme using array-based comparative genomic hybridization. Lab Invest 81: 717-723. (Pubitemid 32466534)
24. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, et al. (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97-109. (Pubitemid 47103521)
25. Nilsson KP, Ikenberg K, Aslund A, Fransson S, Konradsson P, et al. (2010) Structural typing of systemic amyloidoses by luminescent-conjugated polymer spectroscopy. Am J Pathol 176: 563-574.
26. Van Meir E, Sawamura Y, Diserens AC, Hamou MF, de Tribolet N (1990) Human glioblastoma cells release interleukin 6 in vivo and in vitro. Cancer Res 50: 6683-6688. (Pubitemid 20348800)
27. Kaplan EL, Meier P (1958) Nonparametric Estimation from Incomplete Observations. Journal of the American Statistical Association 53: 457-481.
28. Rodak R, Kubota H, Ishihara H, Eugster HP, Konu D, et al. (2005) Induction of reactive oxygen intermediates-dependent programmed cell death in human malignant ex vivo glioma cells and inhibition of the vascular endothelial growth factor production by taurolidine. J Neurosurg 102: 1055-1068. (Pubitemid 43193975)
29. Arcaro A, Doepfner KT, Boller D, Guerreiro AS, Shalaby T, et al. (2007) Novel role for insulin as an autocrine growth factor for malignant brain tumour cells. Biochem J 406: 57-66. (Pubitemid 47264735)
30. Condliffe AM, Davidson K, Anderson KE, Ellson CD, Crabbe T, et al. (2005) Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils. Blood 106: 1432-1440. (Pubitemid 41129612)
31. Chaussade C, Rewcastle GW, Kendall JD, Denny WA, Cho K, et al. (2007) Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling. Biochem J 404: 449-458. (Pubitemid 46953919)
32. Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, et al. (2005) PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat Med 11: 507-514. (Pubitemid 40685973)
33. Sadhu C, Masinovsky B, Dick K, Sowell CG, Staunton DE (2003) Essential role of phosphoinositide 3-kinase delta in neutrophil directional movement. J Immunol 170: 2647-2654. (Pubitemid 36245657)
34. Jamieson S, Flanagan JU, Kolekar S, Buchanan C, Kendall JD, et al. (2011) A drug targeting only p110alpha can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types. Biochem J 438: 53-62.
35. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, et al. (2008) Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 7: 1851-1863.
36. Belkaid A, Copland IB, Massillon D, Annabi B (2006) Silencing of the human microsomal glucose-6-phosphate translocase induces glioma cell death: potential new anticancer target for curcumin. FEBS Lett 580: 3746-3752. (Pubitemid 43902814)
37. Gebäck T, Schulz MM, Koumoutsakos P, Detmar M (2009) TScratch: a novel and simple software tool for automated analysis of monolayer wound healing assays. Biotechniques 46: 265-274.
38. Katso RM, Pardo OE, Palamidessi A, Franz CM, Marinov M, et al. (2006) Phosphoinositide 3-Kinase C2beta regulates cytoskeletal organization and cell migration via Rac-dependent mechanisms. Mol Biol Cell 17: 3729-3744. (Pubitemid 44330861)
39. Hagedorn M, Javerzat S, Gilges D, Meyre A, de Lafarge B, et al. (2005) Accessing key steps of human tumor progression in vivo by using an avian embryo model. Proc Natl Acad Sci U S A 102: 1643-1648. (Pubitemid 40209221)
40. Weigelt B, Downward J (2012) Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer. Front Oncol 2: 109.
41. Gymnopoulos M, Elsliger MA, Vogt PK (2007) Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci U S A 104: 5569-5574. (Pubitemid 47175721)
42. Nicholas MK, Lukas RV, Jafri NF, Faoro L, Salgia R (2006) Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas. Clin Cancer Res 12: 7261-7270. (Pubitemid 46095397)
43. Puputti M, Tynninen O, Sihto H, Blom T, Maenpaa H, et al. (2006) Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas. Mol Cancer Res 4: 927-934. (Pubitemid 46121551)
44. Lino MM, Merlo A (2011) PI3Kinase signaling in glioblastoma. J Neurooncol 103: 417-427.
45. Zhang S, Yu D (2010) PI(3)king apart PTEN's role in cancer. Clin Cancer Res 16: 4325-4330.
46. Carew JS, Kelly KR, Nawrocki ST (2011) Mechanisms of mTOR inhibitor resistance in cancer therapy. Target Oncol 6: 17-27.
47. Akhavan D, Cloughesy TF, Mischel PS (2010) mTOR signaling in glioblastoma: lessons learned from bench to bedside. Neuro Oncol 12: 882-889.
48. Fan QW, Knight ZA, Goldenberg DD, Yu W, Mostov KE, et al. (2006) A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9: 341-349. (Pubitemid 43668732)
49. Koul D, Fu J, Shen R, LaFortune TA, Wang S, et al. (2012) Antitumor activity of NVP-BKM120-a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells. Clin Cancer Res 18: 184-195.
50. Luk SK, Piekorz RP, Nurnberg B, Tony To SS (2012) The catalytic phosphoinositol 3-kinase isoform p110delta is required for glioma cell migration and invasion. Eur J Cancer 48: 149-157.
51. Jia S, Liu Z, Zhang S, Liu P, Zhang L, et al. (2008) Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 454: 776-779.
52. Wee S, Wiederschain D, Maira SM, Loo A, Miller C, et al. (2008) PTEN-deficient cancers depend on PIK3CB. Proc Natl Acad Sci U S A 105: 13057-13062.
53. Janku F, Wheler JJ, Naing A, Falchook GS, Hong DS, et al. (2012) PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early phase clinical trials. Cancer Res.
54. Maira SM, Pecchi S, Huang A, Burger M, Knapp M, et al. (2012) Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor. Mol Cancer Ther 11: 317-328.
55. Kim B, Myung JK, Seo JH, Park CK, Paek SH, et al. (2010) The clinicopathologic values of the molecules associated with the main pathogenesis of the glioblastoma. J Neurol Sci 294: 112-118.
56. McBride SM, Perez DA, Polley MY, Vandenberg SR, Smith JS, et al. (2010) Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival. J Neurooncol 97: 33-40.
57. Ermoian RP, Furniss CS, Lamborn KR, Basila D, Berger MS, et al. (2002) Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival. Clin Cancer Res 8: 1100-1106. (Pubitemid 34517646)
58. Endersby R, Zhu X, Hay N, Ellison DW, Baker SJ (2011) Nonredundant functions for Akt isoforms in astrocyte growth and gliomagenesis in an orthotopic transplantation model. Cancer Res 71: 4106-4116.
59. Mure H, Matsuzaki K, Kitazato KT, Mizobuchi Y, Kuwayama K, et al. (2010) Akt2 and Akt3 play a pivotal role in malignant gliomas. Neuro Oncol 12: 221-232.